NEW YORK (GenomeWeb) – Molecular diagnostics firm Bioarray Genetics on Thursday said that it has received $4 million in Series B equity financing.

The funding came from Quark Venture and GF Securities through their Global Health Science Fund and Connecticut Innovations, and will be used to move Bioarray Genetics' first product, BA100, a breast cancer diagnostic, to clinicians. The financing will also be used for R&D for other tests, including those targeting treatments for metastatic breast and colon cancers, the firm said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.